COMMUNIQUÉS West-GlobeNewswire

TRACON Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
03/09/2019
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, [...]
Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
03/09/2019
MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced [...]
Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics
03/09/2019
Leiden, 3 September 2019 – Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery ’s GS knockout CHO K1 cell line expression system for the development of high [...]
BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
03/09/2019
CAMBRIDGE, Mass. and BEIJING, China, Sept. 03, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
03/09/2019
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, [...]
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September
03/09/2019
BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity [...]
Cybrexa Therapeutics Announces Appointment of Biotech Industry Leader John Houston to Board of Directors
03/09/2019
John Houston brings more than 30 years of experience in drug discovery and development in pharma and biotech as Cybrexa prepares to transition to become a clinical-stage company NEW HAVEN, Conn., Sept. 03, 2019 (GLOBE [...]
Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
03/09/2019
WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, [...]
Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference
03/09/2019
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat [...]
XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference
03/09/2019
EMERYVILLE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the H.C. Wainwright 21 [...]
Passage Bio to Present at Morgan Stanley 17th Annual Global Healthcare Conference
03/09/2019
PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that [...]
Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
03/09/2019
CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ: APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), [...]
Pharmacodynamics Evaluation of PhaseBio’s Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019
03/09/2019
Results from three different assays, including VerifyNow® PRUTest®, demonstrate a high degree of correlation MALVERN, Pa. and SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), [...]
CymaBay Therapeutics to Present at Upcoming Investor Conferences in September
03/09/2019
NEWARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients [...]
GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference
03/09/2019
Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream of [...]
SI-BONE, Inc. Announces Wellmark Blue Cross Blue Shield Establishes Positive Coverage for MIS SI Joint Fusion Using iFuse
03/09/2019
Health New England updates MIS SI joint fusion medical policy to cover iFuse exclusively, the 32nd iFuse exclusive commercial coverage policy SANTA CLARA, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., ( [...]
Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences
03/09/2019
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today [...]
Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication
03/09/2019
Second country in Europe where patients now have access to this important new treatment option; marketing to commence immediately ATLANTA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“ [...]
Kaleido Biosciences Presents Data from Clinical Study of KB195 in Patients with Urea Cycle Disorders at Society for the Study of Inborn Errors of Metabolism Annual Symposium
03/09/2019
Data Demonstrate Safety and Tolerability of Microbiome Metabolic Therapy (MMT™) Candidate KB195 and Potential for Effect on Nitrogen Metabolism, a Biomarker of Ammonia Production LEXINGTON, Mass., Sept. 03, 2019 (GLOBE [...]

Pages